Analyst upgraded Precigen from Underweight to Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/15/2025 | Underweight → Neutral | Analyst | |
| 3/22/2024 | Neutral → Underweight | JP Morgan | |
| 5/23/2023 | Neutral | JP Morgan | |
| 11/18/2022 | $7.00 | Overweight | Cantor Fitzgerald |
4 - PRECIGEN, INC. (0001356090) (Issuer)
4 - PRECIGEN, INC. (0001356090) (Issuer)
4 - PRECIGEN, INC. (0001356090) (Issuer)
8-K - PRECIGEN, INC. (0001356090) (Filer)
8-K - PRECIGEN, INC. (0001356090) (Filer)
10-Q - PRECIGEN, INC. (0001356090) (Filer)
Analyst upgraded Precigen from Underweight to Neutral
JP Morgan downgraded Precigen from Neutral to Underweight
JP Morgan initiated coverage of Precigen with a rating of Neutral
4 - PRECIGEN, INC. (0001356090) (Issuer)
4 - PRECIGEN, INC. (0001356090) (Issuer)
4 - PRECIGEN, INC. (0001356090) (Issuer)
PRGN-2012 has the potential to be the first- and best-in-class treatment for RRPCompany's BLA for PRGN-2012 for the treatment of adults with RRP is under priority review by the FDA with a PDUFA target action date set for August 27, 2025RRP is a rare, debilitating chronic disease with approximately 27,000 adult patients in the US and more than 125,000 patients outside of the USCompany continues to rapidly advance commercial and manufacturing readiness campaign in anticipation of 2025 commercial launch Company and Recurrent Respiratory Papillomatosis Foundation to host the 2025 International RRP Awareness Day on June 11Cash, cash equivalents, and investments of $81.0 million as of March 31, 20
– International event will raise awareness and bring together RRP patients, caregivers, and the healthcare community supporting them –– Recurrent respiratory papillomatosis is a rare, debilitating, chronic disease that impacts both children and adults and is mainly driven by HPV 6/11 infection –– There is no FDA-approved therapeutic for the treatment of RRP, and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease and are associated with significant morbidity and risk of irreversible injury – GERMANTOWN, Md., April 16, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovativ
– Company strengthens focus on building and optimizing commercial readiness and pre-launch activities for PRGN-2012 in recurrent respiratory papillomatosis – GERMANTOWN, Md., July 23, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the appointment of Phil Tennant as the Company's chief commercial officer. Mr. Tennant will be responsible for commercial strategy and execution across US and global markets. His initial focus will be on driving commercial readiness activities for the potential launch of the first- and best-in-class PRGN-2012 Aden
PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with RRP PAPZIMEOS received full approval from the FDA for the treatment of adults with RRP; a confirmatory clinical trial is no longer required RRP is a rare, debilitating, and potentially life-threatening disease caused by chronic HPV 6 or HPV 11 infection, which results in recurrent benign tumors in the respiratory tract; RRP affects an estimated 27,000 adult patients in the USPAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy designed to generate an immune response directed against papilloma cells expressing HPV 6/11—the firs
GERMANTOWN, Md., March 13, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release full year 2024 financial results and provide business updates on Wednesday, March 19, 2025. The Company will host a conference call to discuss results that day at 4:30 PM ET. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in 10-15 minu
GERMANTOWN, Md., Dec. 27, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that it has entered into a securities purchase agreement for the sale of its 8.00% Series A Convertible Perpetual Preferred Stock (Preferred Stock) in a private placement. Precigen anticipates gross proceeds from the private placement of $79.0 million before deducting offering expenses. In addition, the investors will have rights to exercise warrants to purchase 52,666,669 shares of Precigen's common stock at an exercise price of $0.75 per share (Warrants). The offering
SC 13D/A - PRECIGEN, INC. (0001356090) (Subject)
SC 13D/A - PRECIGEN, INC. (0001356090) (Subject)
SC 13G/A - PRECIGEN, INC. (0001356090) (Subject)
PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with RRP PAPZIMEOS received full approval from the FDA for the treatment of adults with RRP; a confirmatory clinical trial is no longer required RRP is a rare, debilitating, and potentially life-threatening disease caused by chronic HPV 6 or HPV 11 infection, which results in recurrent benign tumors in the respiratory tract; RRP affects an estimated 27,000 adult patients in the USPAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy designed to generate an immune response directed against papilloma cells expressing HPV 6/11—the firs
PRGN-2012 has the potential to be the first- and best-in-class treatment for RRPCompany's BLA for PRGN-2012 for the treatment of adults with RRP is under priority review by the FDA with a PDUFA target action date set for August 27, 2025RRP is a rare, debilitating chronic disease with approximately 27,000 adult patients in the US and more than 125,000 patients outside of the USCompany continues to rapidly advance commercial and manufacturing readiness campaign in anticipation of 2025 commercial launch Company and Recurrent Respiratory Papillomatosis Foundation to host the 2025 International RRP Awareness Day on June 11Cash, cash equivalents, and investments of $81.0 million as of March 31, 20
– International event will raise awareness and bring together RRP patients, caregivers, and the healthcare community supporting them –– Recurrent respiratory papillomatosis is a rare, debilitating, chronic disease that impacts both children and adults and is mainly driven by HPV 6/11 infection –– There is no FDA-approved therapeutic for the treatment of RRP, and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease and are associated with significant morbidity and risk of irreversible injury – GERMANTOWN, Md., April 16, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovativ